Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer A randomised phase III trial

Trial summary:

Randomised, controlled phase III trial of systemic anti-cancer therapy (SACT) vs. systemic anti-cancer therapy + radiotherapy in patients with synchronous oligometastatic (1-5 metastases in up to a maximum of 3 organs) non-small cell lung cancer (NSCLC). Patients will be randomised in a 1:1 ratio to either systemic anti-cancer therapy or systemic anti-cancer therapy plus radiotherapy. Patients randomised to the Investigational Arm will receive standard systemic anti-cancer therapy plus radical RT to their primary tumours and to N1-3 mediastinal nodes where present or SABR to their primary if clinically suitable/N0 and SABR and/or SRS to all of themetastatic deposits [Note: SRS is considered standard of care and can be given to all patients enrolled to both Control Arm and Investigational Arm, at any time, i.e. given either, before, during or after conventional RT or systemic anti-cancer therapy if clinically indicated and at the discretion of the treating clinician.

 RT QA summary:

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.

QA ProcessQA ActivityRequired for TrialAdditional Details
Pre-AccrualFacility Questionnaire
Outlining Benchmark CaseUp to 8 cases
Planning Benchmark CaseUp to 8 cases
Dummy Run
During AccrualIndividual Case ReviewProspective if clinician/centre are not fully approved
Data collectionAll patients
QA StreamliningCtE, SEP, TRAP, HALT, SABR QA programmes for pre-accrual and audit

RTTQA contact:

Chief investigator: Fiona McDonald

Sponsor: University College London (

Funder: CRUK